Screener Valuation Movers Economy Bonds Institutions Business Summaries Updates

Screener Summaries Updates Institutions

All content on this site is for informational purposes only and does not constitute financial, investment, legal, or tax advice. Past performance is not indicative of future results. Always consult a qualified financial advisor before making investment decisions.

Financial data is obtained from public filings and third-party providers and is provided “as-is” without any guarantee of accuracy, completeness, or timeliness.

About Privacy Policy Terms of Service Contact

© 2026 go-intrinsic.com. All rights reserved.

Overview Financials Chart Business Summary Filings Ownership Valuation

CRISPR Therapeutics AG (CRSP)

Biological Products, (No Diagnostic Substances)

Latest Price

$52.96

TTM P/E

--

Normalized P/E

--

Div Yield

--

Book Value

18.14

P/B Ratio

2.92

Valuation metrics

adjust assumptions →

Base FCF: $457M (median of recent 5yr)

Growth: 5%/yr (median YOY, capped at 25%)

Discount rate: 10%

Terminal growth: 3%

Projection horizon: 10 years

DCF Fair Value

$101.92

+92% upside